contraindication for tirzepatide What are the contraindications to (Mounjaro) and Semaglutide (Ozempic, Glucagon-like peptide-1 receptor agonist)? The promise of tirzepatide: A

VK2735 VK2735 is an advanced dual GIP/GLP-1 receptor agonist with promising efficacy and the potential to become a major competitor in the injectable obesity market

Reduce symptom discomfort

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

At the American Diabetes Associations 2026 Scientific Sessions, CNBCs Angelica Peebles sat down with Lilly CEO Dave Ricks to discuss exactly who could benefit from the high level of weight loss that the companys next-gen weight loss shot delivers

Get the facts on GLP-1 side effects

Investigational Uses Research is ongoing in: Chronic kidney disease (CKD)[6] Heart failure with preserved ejection fraction (HFpEF)[6][1] Cardiovascular outcomes in obesity[6] Preliminary HFpEF results suggest a 38% reduction in major complications vs placebo[1]